- You can view the full Forest Laboratories Ratings Report.
- Use our drugs section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
- Find other investment ideas from our top rated ETFs lists.
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. Forest Laboratories ( FRX) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 0.5%. By the end of trading, Forest Laboratories rose $0.50 (1.1%) to $44.25 on average volume. Throughout the day, 2,417,789 shares of Forest Laboratories exchanged hands as compared to its average daily volume of 1,620,100 shares. The stock ranged in a price between $42.68-$44.87 after having opened the day at $44.00 as compared to the previous trading day's close of $43.75. Other companies within the Drugs industry that increased today were: IntelliPharmaCeutics International ( IPCI), up 56.0%, Biocryst Pharmaceuticals ( BCRX), up 21.5%, Bacterin International Holdings ( BONE), up 16.9% and DARA Biosciences ( DARA), up 13.0%. Forest Laboratories, Inc. develops, manufactures, and sells branded forms of ethical drug products primarily in the United States and Europe. Forest Laboratories has a market cap of $11.7 billion and is part of the health care sector. Shares are up 23.9% year to date as of the close of trading on Monday. Currently there are 7 analysts that rate Forest Laboratories a buy, 1 analyst rates it a sell, and 8 rate it a hold. TheStreet Ratings rates Forest Laboratories as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income.
